SCHEDULE 13D/A: Lynx1 Capital to Resubmit Neuphoria Buyout Offer

Lynx1 Capital Management plans to resubmit a revised offer to acquire Neuphoria Therapeutics Inc. after the company ceased its dilutive share issuances.

Summary

• Lynx1 Capital Management LP and Weston Nichols beneficially own 875,328 shares of Neuphoria Therapeutics Inc., representing 16.3% of the common stock.
• Neuphoria Therapeutics Inc. disclosed on November 25, 2025, that it ceased its at-the-market (ATM) offering program on November 7, 2025.
• Lynx1 Capital had previously nominated director candidates and made an initial offer to acquire Neuphoria for $5.20 per share.
• This initial offer was withdrawn on November 14, 2025, due to Neuphoria's disclosure of a 128% increase in share count over a four-week period from dilutive issuances.
• Lynx1 Capital is now recalculating and plans to resubmit a revised offer, assuming no further share issuances during the strategic review and accounting for the impact of past "value-destructive" issuances.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant past dilution described as 'value-destructive' and the withdrawal of an initial acquisition offer. While a revised offer is planned, the underlying issues of past dilution and the uncertainty of the new offer's terms weigh heavily.

Positives

• Neuphoria Therapeutics Inc. has ceased its dilutive at-the-market (ATM) offering program, which was a point of contention for Lynx1 Capital.
• Lynx1 Capital Management intends to resubmit a revised offer to acquire Neuphoria, indicating continued interest in a potential acquisition.
• Lynx1 Capital states they "continue to stand behind the economics behind our Initial Offer," suggesting underlying value is still perceived.

Negatives

• Neuphoria Therapeutics Inc. undertook "transformational issuance of shares," increasing the share count by 128% over a four-week period, which Lynx1 Capital described as "massive and potentially continuing dilution at indeterminate prices" and "value-destructive."
• Lynx1 Capital was forced to withdraw its initial offer of $5.20 per share due to this significant dilution.
• The previous dilutive issuances have complicated the valuation process, making it impossible to determine a specific offer price previously.

Risks

• Significant share dilution (128% increase over four weeks) has occurred, impacting existing shareholder value.
• Uncertainty regarding the terms and valuation of the revised acquisition offer from Lynx1 Capital.
• Potential for ongoing strategic review to be prolonged or not result in a definitive acquisition.
• The "value-destructive" nature of past stock issuances could negatively affect future company performance and investor confidence.

Future Outlook

Lynx1 Capital Management is in the process of recalculating and resubmitting a revised offer to acquire Neuphoria Therapeutics Inc., based on the assumption that no further dilutive share issuances will occur during the pendency of the strategic review. The revised offer will incorporate the economics of the previously value-destructive stock issuances.

Management Comments

• "We continue to stand behind the economics behind our Initial Offer."
• "The massive and potentially continuing dilution at indeterminate prices had made it impossible to determine a specific offer price that would capture those economics."
• "As a result of the Company's disclosure that it has ceased issuing shares, we are in the process of recalculating and resubmitting a revised offer based on the assumption that no further issuances will occur during the pendency of the strategic review and incorporating the economics of these value-destructive stock issuances."

Industry Context

This filing highlights a common tension in the biotechnology or early-stage therapeutics industry where companies often rely on dilutive equity financing (like ATM programs) to fund research and development, which can conflict with the interests of significant shareholders or potential acquirers seeking to maintain valuation stability. Lynx1 Capital's actions reflect an activist investor's response to perceived value destruction through excessive dilution, aiming to stabilize the capital structure before proceeding with an acquisition.

Comparison to Industry Standards

• The 128% share count increase over four weeks is an exceptionally high level of dilution, far exceeding typical capital raising activities for established companies and likely raising red flags for corporate governance and shareholder value protection compared to industry best practices.
• Lynx1 Capital's withdrawal and subsequent intent to resubmit an offer, while adjusting for dilution, is a standard activist investor tactic to pressure management and ensure a fair valuation, similar to how other activist funds engage with underperforming or mismanaged companies in the biotech sector.
• The initial offer price of $5.20 per share would need to be benchmarked against recent M&A multiples for comparable early-stage therapeutic companies, considering factors like pipeline stage, clinical trial results, and market potential, which are not detailed in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: Existing shareholders have experienced significant dilution (128% increase in share count) which has negatively impacted their per-share value. The potential for a revised acquisition offer could provide an exit opportunity or a re-evaluation of the company's worth, but the terms are uncertain.
• Potential Acquirer (Lynx1 Capital): Lynx1 Capital's initial offer was disrupted, but they remain committed to an acquisition, albeit at a recalculated price. Their continued engagement suggests a belief in the company's underlying value despite past dilution.
• Management: Management's decision to cease the ATM program indicates a response to shareholder pressure and a potential willingness to engage in a strategic review process.

Next Steps

• Lynx1 Capital Management is recalculating and will resubmit a revised offer to acquire Neuphoria Therapeutics Inc.
• The revised offer will be based on the assumption of no further share issuances during the strategic review.
• The revised offer will incorporate the economics of the past value-destructive stock issuances.

Key Dates

Recommendation

While the cessation of dilutive share issuances is a positive development and Lynx1 Capital's intent to resubmit an offer suggests continued acquisition potential, the massive 128% dilution has significantly altered the company's valuation landscape. The terms of the revised offer are unknown, and the "value-destructive" nature of past issuances creates uncertainty. Investors should hold to await the details of the revised offer and assess its implications for per-share value before making further investment decisions. The situation is fluid, with both positive and negative factors at play.

Keywords

Neuphoria Therapeutics, Lynx1 Capital Management, Schedule 13D, Acquisition Offer, Share Dilution, ATM Offering, Beneficial Ownership, Corporate Governance, Biotechnology, Pharmaceuticals